News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Liberty Global shares trade near $8 after a recent collapse in sentiment.
  • Liberty Global reported EPS of -$8.90 and free cash flow of -$254.8M.
  • Valuation sits around 0.30x book, EV about $8.67B, and EV/EBITDA roughly 7.6x.
  • Trade plan: buy Liberty at $8.00, stop $6.50, target $12.00 over 180 trading days.
  • Microsoft trades near $535 with a P/E of about 30.
  • Microsoft faces a potential $25B incremental AI-related cost base.
  • If Microsoft cuts that cost by about 60%, the stock could reach roughly $856, implying ~60% upside over 180 trading days.

Latest Articles

Kandi Technologies’ China Battery Exchange Secures Follow-On Order for CATL Heavy-Truck Battery Swap Stations

Kandi Technologies’ China Battery Exchange Secures Follow-On Order for CATL Heavy-Truck Battery Swap Stations

Kandi Technologies Group, Inc., through its subsidiary China Battery Exchange, has secured a second batch order for heavy-truck battery swap station equipment from QIJI Energy, a CATL subsidiary. This follows recent agreements and production milestones, marking a transition from product validation to commercial deployment in the heavy-truck battery…

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

Sagimet Biosciences announced a virtual Key Opinion Leader event detailing positive 52-week data from its license partner Ascletis' Phase 3 open-label extension trial of denifanstat in China for moderate to severe acne. The company also outlined plans to initiate its own U.S. Phase 3 AURORA clinical trial in Q4 2026 to further evaluate denifanstat'…

Churchill Downs Incorporated Announces Closing of Amended and Extended Credit Facility and New Term Loan B

Churchill Downs Incorporated Announces Closing of Amended and Extended Credit Facility and New Term Loan B

Churchill Downs Incorporated announced the closing of an amended and extended senior secured credit facility along with a new $500 million Term Loan B due in 2033. The amendment extends the maturity dates on revolving and term loans to 2031, and the new Term Loan B will be used to repay existing loans, cover fees, and support general corporate purp…

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Arvinas, Inc., a clinical-stage biotech company specializing in targeted protein degradation, announced dosing the first patient in its Phase 1/2 trial of ARV-6723, its first immuno-oncology candidate. ARV-6723 is an oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, aiming to enhance antitumor immune responses in adva…

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Tiziana Life Sciences has dosed the first participants in the Phase 2a BANYAN clinical trial studying intranasal foralumab for ALS. The trial aims to evaluate safety, tolerability, and the drug's biological effects on regulatory T cell pathways in ALS patients. Foralumab is a novel, fully human anti-CD3 monoclonal antibody administered intranasally…

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

BlossomHill Therapeutics presented preclinical data demonstrating that their novel pan-KRAS inhibitor BH-501284 exhibits potent and prolonged inhibition of KRAS mutations with deep and durable antitumor activity across multiple cancer models. Designed with a unique Switch-II scaffold and pseudo-irreversible binding, BH-501284 aims to overcome limit…

Eldorado Gold Announces Completion of Skouries Mine Energization

Eldorado Gold Announces Completion of Skouries Mine Energization

Eldorado Gold Corporation announced the successful energization of its Skouries mine in Greece following connection to the national grid, marking a major milestone toward ramping up operations. With first copper-gold concentrate production achieved, Eldorado advances toward expected commercial production in Q4 2026, aiming to produce 140,000 ounces…

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Biotech announced the publication of a peer-reviewed analysis in Frontiers in Cardiovascular Medicine showing no clinical or subclinical cardiotoxicity associated with its anthracycline drug, Annamycin, in a pooled analysis of five clinical trials involving 90 patients. Independent evaluation by the Cleveland Clinic supported these findin…

Aurora Mobile Showcases at Tourism EXPO Japan 2026: How AI is Solving the Travel Industry’s Staffing Crisis

Aurora Mobile Showcases at Tourism EXPO Japan 2026: How AI is Solving the Travel Industry’s Staffing Crisis

Aurora Mobile Limited (NASDAQ: JG) showcased its AI-driven customer engagement and marketing technology solutions at Tourism EXPO Japan 2026, demonstrating how its platforms—EngageLab, GPTBots.ai, and Modellix.ai—help the tourism industry overcome staff shortages and operational inefficiencies. Their AI solutions offer 24/7 multilingual customer su…

Undervalued at the Checkout: A Tactical Long on Ingles Markets (IMKTA)

Undervalued at the Checkout: A Tactical Long on Ingles Markets (IMKTA)

Ingles Markets (IMKTA) is trading below tangible-value metrics despite steady free cash flow, a conservative balance sheet and regional scale. At roughly $1.6B market cap, a P/E near 19.6 and EV/EBITDA ~6.2, the stock looks cheap relative to its fundamentals and resilience. This trade idea lays out an entry at $83.50, stop at $77.00 and a target at…

Bimergen Energy Board Authorizes Warrant Buyback Program

Bimergen Energy Board Authorizes Warrant Buyback Program

Bimergen Energy Corporation, a U.S. developer and operator of utility-scale battery energy storage systems, has authorized an open-market warrant repurchase program. This initiative aims to strategically deploy capital to reduce future equity dilution and optimize the company's equity structure, potentially enhancing long-term value for common stoc…